Literature DB >> 21079150

Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.

Shuling Zhang1, Julie A Readinger, Wendy DuBois, Mirkka Janka-Junttila, Richard Robinson, Margaret Pruitt, Val Bliskovsky, Julie Z Wu, Kaori Sakakibara, Jyoti Patel, Carole A Parent, Lino Tessarollo, Pamela L Schwartzberg, Beverly A Mock.   

Abstract

Mammalian TOR (mTOR) regulates cell growth, proliferation, and migration. Because mTOR knock-outs are embryonic lethal, we generated a viable hypomorphic mouse by neo-insertion that partially disrupts mTOR transcription and creates a potential physiologic model of mTORC1/TORC2 inhibition. Homozygous knock-in mice exhibited reductions in body, organ, and cell size. Although reductions in most organ sizes were proportional to decreased body weight, spleens were disproportionately smaller. Decreases in the total number of T cells, particularly memory cells, and reduced responses to chemokines suggested alterations in T-cell homing/homeostasis. T-cell receptor-stimulated T cells proliferated less, produced lower cytokine levels, and expressed FoxP3. Decreased neutrophil numbers were also observed in the spleen, despite normal development and migration in the bone marrow. However, B-cell effects were most pronounced, with a partial block in B-cell development in the bone marrow, altered splenic populations, and decreases in proliferation, antibody production, and migration to chemokines. Moreover, increased AKT(Ser473) phosphorylation was observed in activated B cells, reminiscent of cancers treated with rapamycin, and was reduced by a DNA-pk inhibitor. Thus, mTOR is required for the maturation and differentiation of multiple immune cell lineages. These mice provide a novel platform for studying the consequences of constitutively reduced mTORC1/TORC2 activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21079150      PMCID: PMC3056471          DOI: 10.1182/blood-2010-05-287821

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Authors:  Timothy R Peterson; Mathieu Laplante; Carson C Thoreen; Yasemin Sancak; Seong A Kang; W Michael Kuehl; Nathanael S Gray; David M Sabatini
Journal:  Cell       Date:  2009-05-14       Impact factor: 41.582

2.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.

Authors:  Greg M Delgoffe; Thomas P Kole; Yan Zheng; Paul E Zarek; Krystal L Matthews; Bo Xiao; Paul F Worley; Sara C Kozma; Jonathan D Powell
Journal:  Immunity       Date:  2009-06-19       Impact factor: 31.745

Review 3.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

4.  Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin.

Authors:  Samik Basu; Tatiana Golovina; Tatiana Mikheeva; Carl H June; James L Riley
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

5.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

6.  Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1.

Authors:  Christian C Dibble; John M Asara; Brendan D Manning
Journal:  Mol Cell Biol       Date:  2009-08-31       Impact factor: 4.272

7.  Follicular shuttling of marginal zone B cells facilitates antigen transport.

Authors:  Guy Cinamon; Marcus A Zachariah; Olivia M Lam; Frank W Foss; Jason G Cyster
Journal:  Nat Immunol       Date:  2007-11-25       Impact factor: 25.606

8.  Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle.

Authors:  Margit Rosner; Christiane Fuchs; Nicol Siegel; Alessandro Valli; Markus Hengstschläger
Journal:  Hum Mol Genet       Date:  2009-06-08       Impact factor: 6.150

9.  The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR.

Authors:  Guangwei Liu; Samir Burns; Gonghua Huang; Kelli Boyd; Richard L Proia; Richard A Flavell; Hongbo Chi
Journal:  Nat Immunol       Date:  2009-05-31       Impact factor: 25.606

10.  Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy.

Authors:  Valérie Risson; Laetitia Mazelin; Mila Roceri; Hervé Sanchez; Vincent Moncollin; Claudine Corneloup; Hélène Richard-Bulteau; Alban Vignaud; Dominique Baas; Aurélia Defour; Damien Freyssenet; Jean-François Tanti; Yannick Le-Marchand-Brustel; Bernard Ferrier; Agnès Conjard-Duplany; Klaas Romanino; Stéphanie Bauché; Daniel Hantaï; Matthias Mueller; Sara C Kozma; George Thomas; Markus A Rüegg; Arnaud Ferry; Mario Pende; Xavier Bigard; Nathalie Koulmann; Laurent Schaeffer; Yann-Gaël Gangloff
Journal:  J Cell Biol       Date:  2009-12-14       Impact factor: 10.539

View more
  79 in total

1.  Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.

Authors:  Jason LeGrand; Eun Sung Park; Hongyang Wang; Shalu Gupta; James D Owens; Patrick J Nelson; Wendy DuBois; Thomas Bair; Siegfried Janz; J Frederic Mushinski
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

Review 2.  Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant.

Authors:  Olivier Thaunat; Alice Koenig; Claire Leibler; Philippe Grimbert
Journal:  J Am Soc Nephrol       Date:  2016-02-12       Impact factor: 10.121

Review 3.  Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.

Authors:  Laura I Salazar-Fontana; Dharmesh D Desai; Tarik A Khan; Renuka C Pillutla; Sandra Prior; Radha Ramakrishnan; Jennifer Schneider; Alexandra Joseph
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

4.  Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression.

Authors:  J Julie Wu; Jie Liu; Edmund B Chen; Jennifer J Wang; Liu Cao; Nisha Narayan; Marie M Fergusson; Ilsa I Rovira; Michele Allen; Danielle A Springer; Cory U Lago; Shuling Zhang; Wendy DuBois; Theresa Ward; Rafael deCabo; Oksana Gavrilova; Beverly Mock; Toren Finkel
Journal:  Cell Rep       Date:  2013-08-29       Impact factor: 9.423

Review 5.  mTOR and other effector kinase signals that impact T cell function and activity.

Authors:  Darienne R Myers; Benjamin Wheeler; Jeroen P Roose
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

6.  mTORC1 activation in B cells confers impairment of marginal zone microarchitecture by exaggerating cathepsin activity.

Authors:  Naresh Kumar Meena; Shakti Prasad Pattanayak; Yael Ben-Nun; Sandrine Benhamron; Saran Kumar; Emmanuelle Merquiol; Nadine Hövelmeyer; Galia Blum; Boaz Tirosh
Journal:  Immunology       Date:  2018-09-16       Impact factor: 7.397

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

8.  Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism.

Authors:  Terri N Iwata; Julita A Ramírez; Mark Tsang; Heon Park; Daciana H Margineantu; David M Hockenbery; Brian M Iritani
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

9.  The transcription factor MZF1 differentially regulates murine Mtor promoter variants linked to tumor susceptibility.

Authors:  Shuling Zhang; Wei Shi; Edward S Ramsay; Valery Bliskovsky; Adrian Max Eiden; Daniel Connors; Matthew Steinsaltz; Wendy DuBois; Beverly A Mock
Journal:  J Biol Chem       Date:  2019-09-23       Impact factor: 5.157

10.  Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

Authors:  Caron A Jacobson; Lixian Sun; Haesook T Kim; Sean M McDonough; Carol G Reynolds; Michael Schowalter; John Koreth; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-23       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.